Current Month 2008
Article Features
  Study Suggests More Asian-American Women May Need to be Tested for BRCA Mutations
The Emotional Work of Disclosing a Diagnosis to Friends and Family
Breast Cancer Confessions: The Emotional Work of Disclosing a Diagnosis
Minorities Less Likely to Know About Breast Cancer Treatment Options
New Treatment for Oral Mucositis in Cancer Patients
Study Shows Radiation Device May Customize Therapy, Enable Some to Avoid Lengthy Treatment
Convenience of Screening Mammography Facilities Plays Major Role in Patient Retention
Perceived Discrimination Affects Screening Rates
Social Class Influences Cancer Risk
Scientists Isolate Cancer Stem Cells
Adding Taxotere to Chemotherapy Regimen Improves Survival in Early Breast Cancer
Young Women with Early Form of Breast Cancer No More Likely to Experience Recurrence than Older Women

Calculating How Breast Cancers Will Respond to Tamoxifen

A discovery by Australian scientists could help clinicians decide which women with breast cancer will make good candidates for anti-estrogen therapies, such as tamoxifen, and which will not.

Over 12,000 Australian women are diagnosed with breast cancer each year, roughly 70% of which will have cancers treatable with tamoxifen. Unfortunately, 30% or more of these women may not respond well to such anti-hormone therapy long-term.

Work done by a research team headed by Associate Professor Liz Musgrove and Professor Rob Sutherland of Sydney's Garvan Institute of Medical Research has correlated expression of certain functionally-related estrogen-regulated genes with predictable clinical outcomes. This expanded knowledge about estrogen action and endocrine resistance should allow clinicians to make better, more informed, choices in the future.

The novel findings were published in the Public Library of Science journal PLoS ONE.

Read More of the Main Article

Visit the Ezine

Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon